Adar Poonawalla, executive director of the Serum Institute, said on Sunday that the Pune-based vaccine manufacturing company obtained authorization from the drug regulator for 50 million doses of the Covishield vaccine, which will be sold at 1,000 rupees to the public and 200 rupees to the public. government. Noting that the University of Oxford-AstraZeneca vaccines are “safe and effective” against coronavirus
Poonawalla added that export of the vaccine has not yet been allowed.
“We have bilaterals with Saudi Arabia and a handful of other countries, but at this time they have not allowed us to export the vaccine. We will ask the government to allow us to do it in a few weeks so we can sell it to another 68” Our company will provide vaccines to warehouses where the states will collect them from, “Poonawalla told News18, adding that the Serum Institute can make 5,000 doses in a minute.
Serum Institute of India had previously said that it has produced around 50 million doses of Oxford-AstraZeneca COVID-19 vaccine ‘Covishield’ and plans to expand it to 100 million in March.
We have already manufactured between 40 and 50 million doses of the vaccine. The launch of the vaccine is expected to be a bit slow in the initial phase due to logistics problems and is expected to recover once things are sorted out, SII Chief Executive Adar Poonawalla told reporters last month. past.
Wishing Indians a happy new year, the Pune-based manufacturer tweeted on Sunday: “All the risks that @SerumInstIndia took in storing the vaccine have finally paid off. COVID-19 the vaccine is approved, safe, effective and ready for implementation in the next few weeks. “
Happy New Year to all! All risks @SerumInstIndia took with the storage of the vaccine, it has finally paid off. COVISHIELD, the first from India COVID-19
– Adar Poonawalla (@adarpoonawalla) January 3, 2021
In addition to SII, Bharat Biotech and Pfizer have also applied to DCGI for an emergency use authorization for their COVID-19 vaccinations However, the eminent clinical scientist and vaccine expert Gagandeep Kang raised concerns about the approval of Bharat Biotech injections, as it is still in phase 3 trials.
Covishield from the Serum Institute of India was the first vaccine recommended for “restricted use” by the government-appointed panel on Friday. Covaxin, the coronavirus Hyderabad-based Bharat Biotech’s vaccine was recommended a day later, on Saturday.
.
